Help protect your four-legged friend from pesky critters with this 6-in-1 broad spectrum monthly Topical Solution for Cats by Revolution Plus. Simply apply the quick-drying, small-volume prescription to help: kill fleas before they lay eggs, kill ticks for a full month, prevent heartworm disease and treat and control roundworms, hookworms and ear mites. This topical medication is suitable for cats and kittens eight weeks of age or older, weighing between 5.6 and 11 pounds.
Proudly sourced directly from the manufacturer or their approved distributor. Guaranteed genuine and backed by the manufacturer.
IMPORTANT SAFETY INFORMATION: See Prescribing Information. The safe use of Revolution Plus has not been established in kittens less than 8 weeks old or in breeding, pregnant or lactating cats. Reported side effects in clinical trials included lethargy and anorexia. Use with caution in cats with a history of neurologic disorders. Sarolaner, one of the ingredients in Revolution Plus, is a member of the isoxazoline class, which has been associated with adverse reactions such as tremors, ataxia, and seizures. Reactions have occurred in cats with or without a history of neurologic disorders. In humans, Revolution Plus may be irritating to skin and eyes.
Revolution Plus is a simple-to-apply, quick-drying, small-volume, monthly topical solution that protects against fleas (Ctenocephalides felis), ticks (black-legged or deer tick [Ixodes scapularis], Gulf Coast tick [Amblyomma maculatum] and American dog tick [Dermacentor variabilis]), ear mites (Otodectes cynotis), roundworms (Toxocara cati), hookworms (Ancylostoma tubaeforme), and heartworms (Dirofilaria immitis) for cats and kittens as young as 8 weeks of age and weighing 2.8 pounds or greater.
- PDFView PDF
Under a Creative Commons license
Open access
Highlights
•
Two clinical field studies were conducted in cats in the United States.
•Selamectin (6–12 mg/kg) plus sarolaner (1–2 mg/kg) provided >95% control of fleas after a single treatment.
•>99% control of fleas was attained after 2 or more monthly treatments.
•Treatment reduced the clinical signs of flea allergy dermatitis.
•94.4% of cats were free of ear mites within one month of treatment.
•There were no serious adverse reactions to treatment with selamectin (6–12 mg/kg) plus sarolaner (1–2 mg/kg).
Abstract
Two randomised, single-masked, multi-center field studies were conducted in the United States in cats presented as veterinary patients. The first study evaluated the efficacy and safety of a topically applied formulation of selamectin plus sarolaner (Revolution® Plus/Stronghold® Plus, Zoetis) against natural flea infestations; the second study evaluated its efficacy against natural ear mite infestations. The product was administered topically by the cats’ owners at the dose range provided in the market product of 6.0–12.0 mg selamectin and 1.0–2.0 mg sarolaner per kg bodyweight. Imidacloprid plus moxidectin (Advantage® Multi for Cats, Bayer) was used as a positive control in both studies at the label dosage. In the flea study, treatments were administered on Days 0, 30, and 60. Efficacy was calculated based on the mean percent reduction of live flea counts on Days 30, 60, and 90 relative to the pre-treatment count. In the ear mite study, a single treatment was applied on Day 0 and efficacy was determined on Days 14 and 30 based on the presence or absence of ear mites. In both studies, patients were randomly allocated to treatments in the ratio of 2:1, selamectin plus sarolaner: imidacloprid plus moxidectin.
In the two studies, 405 cats received treatment with selamectin plus sarolaner; of these, 256 cats received three monthly treatments in the flea study. There were no serious adverse reactions to treatment with selamectin plus sarolaner; health issues noted were typical of the normal ailments or minor traumatic injuries expected in the general cat population and were similar in both treatment groups. Efficacy against fleas based on geometric (arithmetic) means was 97.2% (95.9%), 99.5% (99.4%), and 99.8% (99.8%) in the selamectin plus sarolaner group and was 79.7% (70.5%), 91.4% (77.3%), and 95.5% (87.4%) in the imidacloprid plus moxidectin group on Days 30, 60, and 90, respectively. Flea counts for the selamectin plus sarolaner group were significantly lower than the counts for the imidacloprid plus moxidectin group at all time-points after treatment administration on Day 0 (P < 0.001). Treatment reduced the clinical signs of flea allergy dermatitis (alopecia, dermatitis/pyodermatitis, erythema, pruritus, scaling, and papules) in affected cats by 86.7%–100% in the selamectin plus sarolaner group and by 66.7%–100% in the imidacloprid plus moxidectin group.
In the ear mite study, a single application of selamectin plus sarolaner resulted in the clearance of mites from 87.5% of cats within 14 days and 94.4% of cats within 30 days of treatment. The respective percentages of mite-free cats in the imidacloprid plus moxidectin group were 64.0% and 72.0%. There were significantly more cats with no mites noted in the selamectin plus sarolaner group than in the imidacloprid plus moxidectin group on Day 14 and Day 30 (P ≤ 0.018).
Selamectin plus sarolaner (Revolution® Plus/Stronghold® Plus) administered topically at monthly intervals for three months was well tolerated and highly effective for the treatment and prevention of natural infestations of fleas on cats presented as veterinary patients. Clinical signs of flea allergy dermatitis improved in affected cats following treatment administration. A single topical treatment was also safe and highly effective for the treatment of ear mite infestations in naturally infested cats.
Keywords
Sarolaner
Isoxazoline
Selamectin
Revolution®
Stronghold®
Flea
Ear mite
Efficacy
Safety
Field study
Cited by (0)
© 2018 Zoetis Services LLC. Published by Elsevier B.V.